950
Views
0
CrossRef citations to date
0
Altmetric
Articles

Differences between bone mineral density, lean and fat mass of HIV-positive and HIV-negative black women

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 50-57 | Received 19 Oct 2018, Accepted 27 Feb 2019, Published online: 28 May 2019

References

  • Kruger MC, Kruger IM, Wentzel-Viljoen E, et al. Urbanization of black South African women may increase risk of low bone mass due to low vitamin D status, low calcium intake, and high bone turnover. Nutr Res. 2011;31:748–758. doi: 10.1016/j.nutres.2011.09.012
  • Vorster JNRHH, Venter CS, Kruger MC, et al. The impact of urbanization on risk factors for osteoporosis in black postmenopausal South African women. JEMDSA. 2002;7(3):92–99.
  • Kruger MC, Dewinter RM, Becker PJ, et al. Changes in markers of bone turnover following urbanisation of black South African women. JEMDSA. 2004;9(1):103–108.
  • Ong T, Sahota O, Tan W, et al. A United Kingdom perspective on the relationship between body mass index (BMI) and bone health: a cross sectional analysis of data from the Nottingham Fracture Liaison Service. Bone. 2014;59:207–210. doi: 10.1016/j.bone.2013.11.024
  • Sotunde OF, Kruger HS, Wright HH, et al. Lean mass appears to be more strongly associated with bone health than fat mass in urban black South African women. J Nutr Health Aging. 2015;19(6):628–636. doi: 10.1007/s12603-015-0492-1
  • Aloia JF, Vaswani A, Yeh JK, et al. Risk for osteoporosis in black women. Calcif Tissue Int. 1996;59(6):415–423. doi: 10.1007/BF00369203
  • Handa R, Kalla AA, Maalouf G. Osteoporosis in developing countries. Best Pract Res Clin Rheumatol. 2008;22(4):693–708. doi: 10.1016/j.berh.2008.04.002
  • Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72–75. doi: 10.1016/0140-6736(93)92555-8
  • Serrano S, Marinoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus-1-infected patients. A histo-morphometric study. Bone. 1995;16:185–191. doi: 10.1016/8756-3282(94)00028-X
  • Paton NIJ, Macallan D, Griffin GE, et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int. 1997;61:30–32. doi: 10.1007/s002239900288
  • Compston J. HIV infection and bone disease. JIM. 2016;280:350–358. doi: 10.1111/joim.12520
  • Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108–114. doi: 10.1086/498511
  • Piso RJ, Rothen M, Rothen JP, et al. Per oral substitution with 300000 IU vitamin D (cholecalciferol) reduces bone turnover markers in HIV-infected patients. BMC Infect Dis. 2013;13:577. doi: 10.1186/1471-2334-13-577
  • Wada N, Jacobson LP, Cohen M, et al. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol. 2013;177(2):116–125. doi: 10.1093/aje/kws321
  • Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–831. doi: 10.1097/QAD.0b013e32835192ae
  • Yin MT, Kendall MA, Wu X, et al. Fractures after antiretroviral initiation. AIDS. 2012;26:2175–2184. doi: 10.1097/QAD.0b013e328359a8ca
  • Young B, Dao CN, Buchacz K, et al. HIV outpatientstudy (HOPS) investigators: increased rates of bone fracture among HIV- infected persons in the HIV outpatientstudy (HOPS) compared with the U.S. general population. 2000-2006. Clin Infect Dis. 2011;52:1061–1068. doi: 10.1093/cid/ciq242
  • Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non–HIV-infected patients in a large U.S. healthcare system. J Clin EndocrinMetab. 2008;93:3499–3504. doi: 10.1210/jc.2008-0828
  • Bolland MJ, Grey AB, Gamble GD, et al. Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrin Metab. 2007;92:4522–4528. doi: 10.1210/jc.2007-1660
  • Brown TT, Ross AC, Strorer N, et al. Bone turnover, osteoprtegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;36:482–490.
  • Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013;57(10):1483–1488. doi: 10.1093/cid/cit538
  • Hernandez-Vallejo SJ, Beaupere C, Larghero J, et al. Hiv protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. 2013;12:955–965. doi: 10.1111/acel.12119
  • Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63–F67. doi: 10.1097/00002030-200003100-00005
  • Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with non nucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;27:817–824. doi:10.1097/QAD.0b013e328328f789.
  • Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. 903 Study Group. JAMA. 2004;292:191–201. doi: 10.1001/jama.292.2.191
  • McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–946. doi: 10.1086/656412
  • Stellbrink HJ, Orkin C, Arribas JR, et al. Assert Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–972. doi: 10.1086/656417
  • Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174. doi: 10.1097/QAD.0b013e32801022eb
  • UNAIDS. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic. 2016. Available from: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
  • Alonge TO, Okoje-Adesomoju VN, Atalabi OM, et al. Prevalence of abnormal bone mineral density in HIV-positive patients in Ibadan, Nigeria. J West Afr Coll Surg. 2013;3:1–14.
  • Wentzel-Viljoen E, Laubscher R, Kruger A. Using different approaches to assess the reproducibility of a culturally sensitive quantified food frequency questionnaire. S Afr J Clin Nutr. 2011;24:143–148. doi: 10.1080/16070658.2011.11734366
  • Kruger HS, Venter CS, Steyn HS. A standardised physical activity questionnaire for a population in transition: the Thusa study. Afr J Phys Health Education Recreat Dance. 2000;6:54–64.
  • Norman AW. Receptors for 1α25(OH)2D3: past, present, and future. J Bone Miner Res. 1998;13:1360–1369. doi: 10.1359/jbmr.1998.13.9.1360
  • ISAK. International Standards for Anthropometric Assessment. Potchefstroom, South Africa: The International Society for the Advancement of Kinanthropometry; 2006.
  • Heymsfield SB, Smith R, Aulet M, et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr. 1990;52:214–218. doi: 10.1093/ajcn/52.2.214
  • Chiţu-Tișu CE, Barbu EC, Lazăr M, et al. Low bone mineral density and associated risk factors in HIV-infected patients. GERMS. 2016;6(2):50–59. doi:10.11599/germs.2016.1089.
  • Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. Clin Cases Miner Bone Metab. 2014;11(1):9–14.
  • Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res. 2000;15:322–331. doi: 10.1359/jbmr.2000.15.2.322
  • Zhao S, Zhang YK, Harris S, et al. MLO-Y4 osteocytes-like cells support osteoclast formation and activation. J Bone Miner Res. 2002;17:2068–2079. doi: 10.1359/jbmr.2002.17.11.2068
  • Bow CH, Cheung E, Cheung CL, et al. Ethnic difference of clinical vertebral fracture risk. Osteoporos Int. 2012;23:879–885. doi: 10.1007/s00198-011-1627-9
  • Cheung E, Tsang S, Bow C, et al. Bone loss during menopausal transition among southern Chinese women. Maturitas. 2011;69(1):50–56. doi: 10.1016/j.maturitas.2011.01.010
  • Marcason W. What is the effect of a high protein diet on bone health? J Am Diet Assoc. 2010;3:34.
  • Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone mineral density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19:913–918. doi: 10.1007/s00198-007-0524-8
  • Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16:1345–1352. doi: 10.1007/s00198-005-1845-0
  • Shiau S, Broun EC, Arpadi SM, et al. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013;27:1949–1957. doi: 10.1097/QAD.0b013e328361d241
  • Dave JA, Cohen K, Mickelsfield LK, et al. Antiretroviral therapy, especially efavirenz is associated with bone mineral density in HIV infected South Africans. PLoS ONE. 2015;10(12):e0144286. doi:10.1371/journal.Pone. 0144286 doi: 10.1371/journal.pone.0144286
  • Mulubwa M, Viljoen M, Kruger IM, et al. Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy. S Afr J HIV Med. 2017;18(1):9739. doi:10.4102/sajhivmed.v18i1.739.
  • Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482–490. doi: 10.1086/367569
  • Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275–1280. doi: 10.1097/00002030-200107060-00009
  • Mora S, Sala N, Bricalli D, et al. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15:1823–1829. doi: 10.1097/00002030-200109280-00011
  • Havens PL, Kiser JJ, Stephensen CB, et al. Adolescent Medicine Trials network for HIV/AIDS Interventions (ATN) 063 Study Team. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 2013;57:5619–5628. doi:10.1128/AAC.01096-13.
  • Overton ET, Chan ES, Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation. Ann Intern Med. 2015;162:815–824. doi:10.7326/M14-1409.
  • Macintyre UE, Kruger HS, Venter CS, et al. Dietary intakes of an African population in different stages of transition in the North West Province, South Africa: the THUSA study. Nutr Res. 2002;22:239–256. doi: 10.1016/S0271-5317(01)00392-X
  • Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioural factors. J Womens Health. 2006;15(6):709–719. doi: 10.1089/jwh.2006.15.709
  • Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. Br Med J. 2010;341:c3691. doi: 10.1136/bmj.c3691
  • Li K, Kaaks R, Linseisen J, et al. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart. 2012;98:920–925. doi: 10.1136/heartjnl-2011-301345
  • Galli L, Rubinacci A, Cocorullo D, et al. Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk. Clin Nutr. 2014;33:363–366. doi: 10.1016/j.clnu.2013.07.004
  • Mendoza N, De Teresa C, Cano A, et al. Benefits of physical exercise in postmenopausal women. Maturitas. 2016;93:83–88. doi:10.1016/j.maturitas.2016.04.017.
  • Xu J, Lombardi G, Jiao W, et al. Effects of exercise on bone status in female subjects, from young girls to postmenopausal women: an overview of systematic reviews and meta-analyses. Sports Med. 2016;46(8):1165–1182. doi:10.1007/s40279-016-0494-0.
  • Santos WR, Santos WR, Paes PP, et al. Impact of strength training on bone mineral density in patients infected with HIV exhibiting lipodystrophy. J Strenght Cond Res. 2015;29(12):3466–3471. doi:10.1519/JSC.0000000000001001.
  • Bonato M, Bossolasco S, Galli L, et al. Moderate aerobic exercise (brisk walking) increases bone density in cART-treated persons. JIAS. 2012;15(4):18318. doi:10.7448/IAS.15.6.18318.
  • Perazzo JD, Webel AR, Alam SMK, et al. Relationships between physical activity and bone density in people living with HIV: results from the SATURN-HIV Study. JANAC. 2018;29(4):528–537.